Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens

Journal of Infection and Chemotherapy

Volumn 19, Issue 1, 2013, Pages 57-62

  Yilmaz, Gül R ^a,b   Baştuǧ, Aliye Tanrici ^a   But, Ayşe ^a   Yildiz, Sümeyye ^a   Yetkin, M Arzu ^a   Kanyilmaz, Dilek ^a   Akinci, Esragül ^a   Bodur, Hürrem ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Colistin; Efficacy; Toxicity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BLOODSTREAM INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; LEUKOCYTOSIS; LEUKOPENIA; MALE; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; TURKEY (REPUBLIC); URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84874106093     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0451-2     Document Type: Article

References (23)

1. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents. 2005;26:504-7.
2. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2006;25:596-9.
3. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant gram-negative bacterial infections. Clin Microbiol Infect. 2006;12:1227-30.
4. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis. 2005;5:1.
5. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.
6. American Thoracic Society and Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
7. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-32.
8. Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayhall CG, editor. Hospital epidemiology and infection control. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1659-702.
9. Flanagan AD. Adverse effects of sodium colistimethate. Ann Intern Med. 1971;74:143-4.
10. Randall RE, Bridi GS, Setter JG, Brackett NC. Recovery from colistimethate nephrotoxicity. Ann Intern Med. 1970;73:491-2.
11. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis. 2007;11:402-6.
12. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care. 2003;7:78-83.
13. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003;47:2659-62.
14. Levin AS, Barone AA, Penco J, Santos MI, Marinho IS, Arruda EAG, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:2008-11.
15. Cheng CY, Sheng WH, Wang JY, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents. 2010;35:297-300.
16. Gilbert DN, Moellering RC, Eliopoulas G, Chambers HF, Saag MS (eds) (2010) The Sanford guide to antimicrobial therapy, 40th edn. Antimicrobial Therapy, Inc., Sperryville, VA
17. David M, Gill MJ. Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. J Antimicrob Chemother. 2008;61:962-4.
18. Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents. 2009;33:503.
19. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56:432-6.
20. Furtado GH, d'Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007;30:315-9.
21. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother. 2006;40:1939-45.
22. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 2008;61:1369-75.
23. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54:4503-5.